Upadacitinib可有效降低中度至重度特应性皮炎成人患者的述情特征:一项前瞻性多中心现实研究。

IF 2.6 4区 医学 Q3 DERMATOLOGY
Eustachio Nettis, Mattia Cristallo, Carmen S Fiorella, Angela Giuliani, Vincenzo Patella, Luciana Pierro, Tiziana Peduto, Giuseppe F Amoruso, Genoveffa Scotto DI Luzio, Pietro Morrone, Martino Carriero, Pierfrancesco DE Giacomo, Massimo Triggiani, Isabella Carrieri, Ippolita Zaza, Francesco Pugliese, Marina Castriota, Stefano Pellè
{"title":"Upadacitinib可有效降低中度至重度特应性皮炎成人患者的述情特征:一项前瞻性多中心现实研究。","authors":"Eustachio Nettis, Mattia Cristallo, Carmen S Fiorella, Angela Giuliani, Vincenzo Patella, Luciana Pierro, Tiziana Peduto, Giuseppe F Amoruso, Genoveffa Scotto DI Luzio, Pietro Morrone, Martino Carriero, Pierfrancesco DE Giacomo, Massimo Triggiani, Isabella Carrieri, Ippolita Zaza, Francesco Pugliese, Marina Castriota, Stefano Pellè","doi":"10.23736/S2784-8671.25.08228-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Upadacitinib has proven to be well tolerated and provided superior efficacy compared to dupilumab after 16 weeks of treatment in adult patients with moderate-to-severe atopic dermatitis (AD) in randomized clinical trials.</p><p><strong>Methods: </strong>This multicentric, prospective, observational, real-life study included 120 adult patients with moderate-to-severe AD treated with Upadacitinib at 10 Italian hospitals. We examined both physician-reported outcome measures (EASI), patient-reported outcome measures (itch, sleep and pain score [NRS], Dermatology Life Quality Index [DLQI], alexithymia [TAS-20 score]), and serological markers after 16 weeks.</p><p><strong>Results: </strong>A statistically significant reduction was recorded in all the scores analyzed, including the TAS-20 score (P<0.0001). The median (IQR) change from baseline to 16 weeks of treatment in the EASI score was 90.1 (11.3) (P<0.0001). The EASI50, EASI75 and EASI90 response rates were 95.8%, 82.5%, 50.8% (P<0.0001).</p><p><strong>Conclusions: </strong>This is the broadest multicenter real-life study in AD patients treated with upadacitinib, analyzing the reduction of the TAS-20 score. Noteworthy is the rapidity of drug effectiveness in reducing the extension of lesions and itching after just four weeks.</p>","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":"160 5","pages":"398-405"},"PeriodicalIF":2.6000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Upadacitinib is efficacious in reducing the alexithymic trait in adult patients with moderate-to-severe atopic dermatitis: a prospective multicenter real-life study.\",\"authors\":\"Eustachio Nettis, Mattia Cristallo, Carmen S Fiorella, Angela Giuliani, Vincenzo Patella, Luciana Pierro, Tiziana Peduto, Giuseppe F Amoruso, Genoveffa Scotto DI Luzio, Pietro Morrone, Martino Carriero, Pierfrancesco DE Giacomo, Massimo Triggiani, Isabella Carrieri, Ippolita Zaza, Francesco Pugliese, Marina Castriota, Stefano Pellè\",\"doi\":\"10.23736/S2784-8671.25.08228-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Upadacitinib has proven to be well tolerated and provided superior efficacy compared to dupilumab after 16 weeks of treatment in adult patients with moderate-to-severe atopic dermatitis (AD) in randomized clinical trials.</p><p><strong>Methods: </strong>This multicentric, prospective, observational, real-life study included 120 adult patients with moderate-to-severe AD treated with Upadacitinib at 10 Italian hospitals. We examined both physician-reported outcome measures (EASI), patient-reported outcome measures (itch, sleep and pain score [NRS], Dermatology Life Quality Index [DLQI], alexithymia [TAS-20 score]), and serological markers after 16 weeks.</p><p><strong>Results: </strong>A statistically significant reduction was recorded in all the scores analyzed, including the TAS-20 score (P<0.0001). The median (IQR) change from baseline to 16 weeks of treatment in the EASI score was 90.1 (11.3) (P<0.0001). The EASI50, EASI75 and EASI90 response rates were 95.8%, 82.5%, 50.8% (P<0.0001).</p><p><strong>Conclusions: </strong>This is the broadest multicenter real-life study in AD patients treated with upadacitinib, analyzing the reduction of the TAS-20 score. Noteworthy is the rapidity of drug effectiveness in reducing the extension of lesions and itching after just four weeks.</p>\",\"PeriodicalId\":14526,\"journal\":{\"name\":\"Italian Journal of Dermatology and Venereology\",\"volume\":\"160 5\",\"pages\":\"398-405\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Italian Journal of Dermatology and Venereology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.23736/S2784-8671.25.08228-3\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Italian Journal of Dermatology and Venereology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.23736/S2784-8671.25.08228-3","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:在随机临床试验中,Upadacitinib在治疗中度至重度特应性皮炎(AD)的成人患者16周后,已被证明具有良好的耐受性,并且与dupilumab相比具有优越的疗效。方法:这项多中心、前瞻性、观察性、现实研究纳入了意大利10家医院接受Upadacitinib治疗的120例中重度AD成年患者。我们在16周后检查了医生报告的结果测量(EASI)、患者报告的结果测量(瘙痒、睡眠和疼痛评分[NRS]、皮肤病生活质量指数[DLQI]、述情障碍[TAS-20评分])和血清学指标。结果:所有分析的评分均有统计学显著降低,包括TAS-20评分(p结论:这是在upadacitinib治疗的AD患者中最广泛的多中心现实研究,分析了TAS-20评分的降低。值得注意的是,药物在减少病变和瘙痒的扩展仅四周后的快速有效性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Upadacitinib is efficacious in reducing the alexithymic trait in adult patients with moderate-to-severe atopic dermatitis: a prospective multicenter real-life study.

Background: Upadacitinib has proven to be well tolerated and provided superior efficacy compared to dupilumab after 16 weeks of treatment in adult patients with moderate-to-severe atopic dermatitis (AD) in randomized clinical trials.

Methods: This multicentric, prospective, observational, real-life study included 120 adult patients with moderate-to-severe AD treated with Upadacitinib at 10 Italian hospitals. We examined both physician-reported outcome measures (EASI), patient-reported outcome measures (itch, sleep and pain score [NRS], Dermatology Life Quality Index [DLQI], alexithymia [TAS-20 score]), and serological markers after 16 weeks.

Results: A statistically significant reduction was recorded in all the scores analyzed, including the TAS-20 score (P<0.0001). The median (IQR) change from baseline to 16 weeks of treatment in the EASI score was 90.1 (11.3) (P<0.0001). The EASI50, EASI75 and EASI90 response rates were 95.8%, 82.5%, 50.8% (P<0.0001).

Conclusions: This is the broadest multicenter real-life study in AD patients treated with upadacitinib, analyzing the reduction of the TAS-20 score. Noteworthy is the rapidity of drug effectiveness in reducing the extension of lesions and itching after just four weeks.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.10
自引率
0.00%
发文量
442
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信